Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
2019
PURPOSENivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metas...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
99
Citations
NaN
KQI